La Jolla, CA-based startup Intellikine has quickly racked up 1,500 drug candidates that can influence the PI3 kinase pathway, an indication of the biotech company's intensity and a key reason it has been able to attract considerable support from the venture capital community.
Xconomy's Luke Timmerman profiles the company and its CEO, Troy Wilson, who has collected $28 million in a venture round that could total $51 million.
"We may not be first in class, but we want to be best in class," Wilson tells the tech news site. "We wanted to look at every possible kind of inhibitor."
- read the profile from Xconomy